FcRn Inhibitor Batoclimab Meets Key Endpoint in Phase 3 Study in Myasthenia Gravis

Published Date: 12 Mar 2023

Batoclimab, a fully human anti-FcRn monoclonal antibody, has been shown to reduce symptoms and improve quality of life in patients with myasthenia gravis.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Doctors say lung cancer is still the deadliest cancer, but hope is growing

2.

Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.

3.

FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.

4.

The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.

5.

Virtual Reality Travel Reduces Cancer Pain.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot